GlaxoSmithKiline seeks authorisation for type-2 diabetes treatment

FTSE-100 listed pharmaceutical giant GlaxoSmithKline (GSK) has submitted a marketing authorisation application (MAA) for its albiglutide treatment to the European Medicines Agency (EMA). The product is an investigational once-weekly treatment for adult patients with type-2 diabetes which is not yet approved anywhere in the world.The company also made a submission for albiglutide's regulatory application in the US. Studies of albiglutide have shown that it rapidly degrades GLP-1, a peptide that is normally secreted from the gastrointestinal tract during a meal which in turn helps release insulin to control blood sugar elevations after eating, but which is reduced or absent in a person with type-2 diabetes. GSK's share price was 0.48% higher at 1,480p by 13:15 Thursday.NR